We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-4.61%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$4.5B
AUM Growth
-$546M
Cap. Flow
-$26.9M
Cap. Flow %
-0.6%
Top 10 Hldgs %
82.03%
Holding
109
New
17
Increased
29
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$24.5M
2
ATH
Athene Holding Ltd. Class A Common Shares
ATH
+$18.5M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
4
ZTO icon
ZTO Express
ZTO
+$14.4M
5
CELG
Celgene Corp
CELG
+$11.1M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$32.3M
2
BAC icon
Bank of America
BAC
+$19.3M
3
ARRY
Array Biopharma Inc
ARRY
+$16.6M
4
MS icon
Morgan Stanley
MS
+$13.2M
5
APTV icon
Aptiv
APTV
+$10.7M

Sector Composition

Rank Sector Weight
1 Consumer Staples 46.77%
2 Healthcare 26.64%
3 Miscellaneous 17.93%
4 Consumer Discretionary 7.97%
5 Financials 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
CALL
Nektar Therapeutics
NKTR
$2.3B
$6.13M 0.14%
+33,333
New +$6.78M
NBIX icon
52
Neurocrine Biosciences
NBIX
$15.5B
$5.8M 0.13%
150,000
+50,000
+50% +$2.26M
SRPT icon
53
Sarepta Therapeutics
SRPT
$2.16B
$5.49M 0.12%
200,000
– –
LCTX icon
54
Lineage Cell Therapeutics
LCTX
$260M
$4.63M 0.1%
1,465,383
– –
RXDX
55
DELISTED
Ignyta, Inc.
RXDX
$4.5M 0.1%
850,000
– –
ELF icon
56
e.l.f. Beauty
ELF
$5.72B
$4.34M 0.1%
150,000
– –
MGNX icon
57
MacroGenics
MGNX
$254M
$4.09M 0.09%
200,000
+50,000
+33% +$1.26M
CCXI
58
DELISTED
ChemoCentryx, Inc.
CCXI
$4.04M 0.09%
546,278
-653,722
-54% -$4.71M
NBIX icon
59
CALL
Neurocrine Biosciences
NBIX
$15.5B
$3.87M 0.09%
+100,000
New +$4.53M
XLRN
60
DELISTED
Acceleron Pharma
XLRN
$3.83M 0.09%
150,000
-25,000
-14% -$792K
RDUS
61
DELISTED
Radius Health, Inc.
RDUS
$3.8M 0.08%
100,000
+50,000
+100% +$2.38M
JUNO
62
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.77M 0.08%
200,000
– –
SIOX
63
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.73M 0.08%
37,500
+6,250
+20% +$658K
GBT
64
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.56M 0.08%
246,054
+146,054
+146% +$2.57M
RARE icon
65
Ultragenyx Pharmaceutical
RARE
$1.3B
$3.52M 0.08%
50,000
– –
NTLA icon
66
Intellia Therapeutics
NTLA
$1.6B
$3.28M 0.07%
250,000
+45,000
+22% +$676K
ACIU icon
67
AC Immune
ACIU
$258M
$3.25M 0.07%
250,000
+100,000
+67% +$1.38M
FOLD
68
CALL
DELISTED
Amicus Therapeutics
FOLD
$3.23M 0.07%
650,000
– –
LOXO
69
DELISTED
Loxo Oncology, Inc
LOXO
$3.21M 0.07%
100,000
+25,000
+33% +$641K
RGNX icon
70
Regenxbio
RGNX
$540M
$2.97M 0.07%
160,000
-140,000
-47% -$2.68M
NERV icon
71
Minerva Neurosciences
NERV
$179M
$2.95M 0.07%
31,413
+6,413
+26% +$655K
CLLS
72
Cellectis
CLLS
$165M
$2.54M 0.06%
150,000
– –
ONCE
73
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.5M 0.06%
50,000
– –
CLDX icon
74
Celldex Therapeutics
CLDX
$2.97B
$2.39M 0.05%
45,000
– –
CMRX
75
DELISTED
Chimerix, Inc.
CMRX
$2.3M 0.05%
500,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2016 Portfolio in Review

As of Q4 2016, Artal Group held 109 positions worth $4.5B, down 11% from $5.05B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Artal Group's Q4 2016 filing shows 17 new, 29 increased, 12 reduced and 18 closed positions. Its largest new stake was Alexion Pharmaceuticals: 200,000 shares worth $24.5M. The largest sale was Goldman Sachs, an estimated $32.3M.

By sector, the portfolio is most concentrated in Consumer Staples at 47% of assets, up from 41% a quarter earlier, followed by Healthcare and Miscellaneous.

  • Artal Group's largest Q4 2016 buy was Alexion Pharmaceuticals: 200,000 shares worth $24.5M.
  • Artal Group added most to Agios Pharmaceuticals in Q4 2016, an estimated $18.4M increase.
  • Artal Group's biggest Q4 2016 reduction was Array Biopharma Inc, cutting an estimated $16.6M.
  • Artal Group fully exited Goldman Sachs in Q4 2016, selling an estimated $32.3M.
  • Artal Group's ten largest holdings make up 82% of its $4.5B portfolio in Q4 2016.
  • Artal Group opened 17 new positions and closed 18 in Q4 2016.
  • Artal Group's portfolio value fell 11% quarter-over-quarter to $4.5B.

Based on Artal Group's 13F filing for Q4 2016, filed 14 Feb 2017.